172 related articles for article (PubMed ID: 19501128)
1. Cord blood stem cell expansion is permissive to epigenetic regulation and environmental cues.
Araki H; Baluchamy S; Yoshinaga K; Petro B; Petiwala S; Parajuli R; Milhem M; Lavelle D; DeSimone J; Mahmud N
Exp Hematol; 2009 Sep; 37(9):1084-95. PubMed ID: 19501128
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers.
Saraf S; Araki H; Petro B; Park Y; Taioli S; Yoshinaga KG; Koca E; Rondelli D; Mahmud N
Transfusion; 2015 Apr; 55(4):864-74. PubMed ID: 25363624
[TBL] [Abstract][Full Text] [Related]
3. Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents.
Araki H; Mahmud N; Milhem M; Nunez R; Xu M; Beam CA; Hoffman R
Exp Hematol; 2006 Feb; 34(2):140-9. PubMed ID: 16459182
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells.
Mahmud N; Petro B; Baluchamy S; Li X; Taioli S; Lavelle D; Quigley JG; Suphangul M; Araki H
Biol Blood Marrow Transplant; 2014 Apr; 20(4):480-9. PubMed ID: 24374212
[TBL] [Abstract][Full Text] [Related]
5. Chromatin-modifying agents permit human hematopoietic stem cells to undergo multiple cell divisions while retaining their repopulating potential.
Araki H; Yoshinaga K; Boccuni P; Zhao Y; Hoffman R; Mahmud N
Blood; 2007 Apr; 109(8):3570-8. PubMed ID: 17185465
[TBL] [Abstract][Full Text] [Related]
6. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.
Wang X; Zhang W; Tripodi J; Lu M; Xu M; Najfeld V; Li Y; Hoffman R
Blood; 2010 Dec; 116(26):5972-82. PubMed ID: 20858855
[TBL] [Abstract][Full Text] [Related]
7. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.
Milhem M; Mahmud N; Lavelle D; Araki H; DeSimone J; Saunthararajah Y; Hoffman R
Blood; 2004 Jun; 103(11):4102-10. PubMed ID: 14976039
[TBL] [Abstract][Full Text] [Related]
8. Chromatin-Modifying Agent-Expanded Human Cord Blood Cells Display Reduced Allostimulatory Capacity.
Petro B; Mahmud D; Taioli S; Ganapathy A; Senyuk V; Yoshinaga KG; Suphangul M; Rondelli D; Mahmud N
J Immunol; 2019 Apr; 202(8):2493-2501. PubMed ID: 30842275
[TBL] [Abstract][Full Text] [Related]
9. CD34+ cells from mobilized peripheral blood retain fetal bone marrow repopulating capacity within the Thy-1+ subset following cell division ex vivo.
Young JC; Lin K; Hansteen G; Travis M; Murray LJ; Jaing L; Scollay R; Hill BL
Exp Hematol; 1999 Jun; 27(6):994-1003. PubMed ID: 10378888
[TBL] [Abstract][Full Text] [Related]
10. Human stem-progenitor cells from neonatal cord blood have greater hematopoietic expansion capacity than those from mobilized adult blood.
Tanavde VM; Malehorn MT; Lumkul R; Gao Z; Wingard J; Garrett ES; Civin CI
Exp Hematol; 2002 Jul; 30(7):816-23. PubMed ID: 12135681
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic reprogramming induces the expansion of cord blood stem cells.
Chaurasia P; Gajzer DC; Schaniel C; D'Souza S; Hoffman R
J Clin Invest; 2014 Jun; 124(6):2378-95. PubMed ID: 24762436
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Different Cytokine Conditions Reveals Resveratrol as a New Molecule for Ex Vivo Cultivation of Cord Blood-Derived Hematopoietic Stem Cells.
Heinz N; Ehrnström B; Schambach A; Schwarzer A; Modlich U; Schiedlmeier B
Stem Cells Transl Med; 2015 Sep; 4(9):1064-72. PubMed ID: 26160960
[TBL] [Abstract][Full Text] [Related]
13. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis.
Shi J; Zhao Y; Ishii T; Hu W; Sozer S; Zhang W; Bruno E; Lindgren V; Xu M; Hoffman R
Cancer Res; 2007 Jul; 67(13):6417-24. PubMed ID: 17616702
[TBL] [Abstract][Full Text] [Related]
14. Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice.
Peled T; Landau E; Mandel J; Glukhman E; Goudsmid NR; Nagler A; Fibach E
Exp Hematol; 2004 Jun; 32(6):547-55. PubMed ID: 15183895
[TBL] [Abstract][Full Text] [Related]
15. Co-culture of human CD34+ cells with mesenchymal stem cells increases the survival of CD34+ cells against the 5-aza-deoxycytidine- or trichostatin A-induced cell death.
Koh SH; Choi HS; Park ES; Kang HJ; Ahn HS; Shin HY
Biochem Biophys Res Commun; 2005 Apr; 329(3):1039-45. PubMed ID: 15752760
[TBL] [Abstract][Full Text] [Related]
16. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.
Wang X; Zhang W; Ishii T; Sozer S; Wang J; Xu M; Hoffman R
Cancer Res; 2009 Oct; 69(19):7612-8. PubMed ID: 19752087
[TBL] [Abstract][Full Text] [Related]
17. Preclinical ex vivo expansion of cord blood hematopoietic stem and progenitor cells: duration of culture; the media, serum supplements, and growth factors used; and engraftment in NOD/SCID mice.
Lam AC; Li K; Zhang XB; Li CK; Fok TF; Chang AM; James AE; Tsang KS; Yuen PM
Transfusion; 2001 Dec; 41(12):1567-76. PubMed ID: 11778074
[TBL] [Abstract][Full Text] [Related]
18. Dissociation between stem cell phenotype and NOD/SCID repopulating activity in human peripheral blood CD34(+) cells after ex vivo expansion.
Danet GH; Lee HW; Luongo JL; Simon MC; Bonnet DA
Exp Hematol; 2001 Dec; 29(12):1465-73. PubMed ID: 11750106
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34(+) cord blood cells.
Kobari L; Pflumio F; Giarratana M; Li X; Titeux M; Izac B; Leteurtre F; Coulombel L; Douay L
Exp Hematol; 2000 Dec; 28(12):1470-80. PubMed ID: 11146169
[TBL] [Abstract][Full Text] [Related]
20. Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465).
Tatetsu H; Armant M; Wang F; Gao C; Ueno S; Tian X; Federation A; Qi J; Bradner J; Tenen DG; Chai L
Exp Hematol; 2019 Jul; 75():53-63.e11. PubMed ID: 31260717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
